

WHAT IS CLAIMED IS:

1. An immunogenic composition which comprises a first malaria-derived peptide comprising a universal T-cell epitope, wherein said composition elicits an anti-malarial T-cell response in mammals of diverse genetic backgrounds.
2. An immunogenic composition as defined in claim 1, further comprising a second malaria-derived peptide comprising a B-cell epitope which stimulates the production of anti-malarial antibodies in mammals.
3. An immunogenic composition as defined in claim 1, wherein said first peptide is incorporated into a multiple antigen peptide (MAP).
4. An immunogenic composition as defined in claim 2, wherein said first and second peptides are incorporated into a multiple antigen peptide (MAP).
5. An immunogenic composition as defined in claim 1, wherein said first peptide comprises the sequence EYLNKIQNSLSTEWSPCSVT (SEQ ID NO:3).
6. An immunogenic composition as defined in claim 1, wherein said first peptide consists essentially of the sequence EYLNKIQNSLSTEWSPCSVT (SEQ ID NO:3).
7. A vaccine comprising an immunogenic composition as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.
8. A vaccine as defined in claim 7, further comprising a pharmaceutically acceptable adjuvant.

9. A method for inhibiting the propagation of a malarial organism in a susceptible mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 7.

10. A method for eliciting protective immunity against malaria in a mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 7.

11. An immunogenic composition which comprises a first malaria-derived peptide comprising the sequence EYLNKIQNSLSTEWSPCSVT (SEQ ID NO:3), wherein said composition elicits an anti-malarial T-cell response in mammals of diverse genetic backgrounds.

12. An immunogenic composition as defined in claim 11, further comprising a second malaria-derived peptide comprising a B-cell epitope which stimulates the production of anti-malarial antibodies in mammals.

13. A vaccine comprising an immunogenic composition as defined in claim 11 and a pharmaceutically acceptable carrier or diluent.

14. A vaccine as defined in claim 13, further comprising a pharmaceutically acceptable adjuvant.

15. A method for inhibiting the propagation of a malarial organism in a susceptible mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 13.

16. A method for eliciting protective immunity against malaria in a mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 13.

17. An immunogenic composition which comprises a first malaria-derived peptide consisting essentially of the sequence EYLNKIQNSLSTEWSPCSVT (SEQ ID NO:3), wherein said composition elicits an anti-malarial T-cell response in mammals of diverse genetic backgrounds.

18. A vaccine comprising an immunogenic composition as defined in claim 17 and a pharmaceutically acceptable carrier or diluent.

19. A method for inhibiting the propagation of a malarial organism in a susceptible mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 18.

20. A method for eliciting protective immunity against malaria in a mammal, which comprises administering to said mammal an immunogenically effective amount of a vaccine as defined in claim 18.